FR2970969B1 - Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique - Google Patents

Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique

Info

Publication number
FR2970969B1
FR2970969B1 FR1150645A FR1150645A FR2970969B1 FR 2970969 B1 FR2970969 B1 FR 2970969B1 FR 1150645 A FR1150645 A FR 1150645A FR 1150645 A FR1150645 A FR 1150645A FR 2970969 B1 FR2970969 B1 FR 2970969B1
Authority
FR
France
Prior art keywords
preparation
oligosaccharides
fgfs
receptors
therapeutic application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1150645A
Other languages
English (en)
Other versions
FR2970969A1 (fr
Inventor
Pierre Alexandre Driguez
Philippe Duchaussoy
Pierre Fons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR1150645A priority Critical patent/FR2970969B1/fr
Priority to ARP120100256A priority patent/AR084924A1/es
Priority to EP12703584.8A priority patent/EP2668198A1/fr
Priority to PCT/IB2012/050390 priority patent/WO2012101605A1/fr
Priority to CN2012800153345A priority patent/CN103443114A/zh
Priority to JP2013550994A priority patent/JP2014503674A/ja
Priority to TW101102918A priority patent/TW201236687A/zh
Publication of FR2970969A1 publication Critical patent/FR2970969A1/fr
Priority to US13/951,820 priority patent/US20140094429A1/en
Application granted granted Critical
Publication of FR2970969B1 publication Critical patent/FR2970969B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
FR1150645A 2011-01-27 2011-01-27 Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique Expired - Fee Related FR2970969B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1150645A FR2970969B1 (fr) 2011-01-27 2011-01-27 Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
ARP120100256A AR084924A1 (es) 2011-01-27 2012-01-26 Oligosacaridos 3-o-alquilados activadores de los receptores de los fgf y una composicion farmaceutica en base al compuesto
PCT/IB2012/050390 WO2012101605A1 (fr) 2011-01-27 2012-01-27 3-o-alkyl-oligosaccharides activateurs de récepteur fgf, préparation de ceux-ci et utilisation thérapeutique de ceux-ci
CN2012800153345A CN103443114A (zh) 2011-01-27 2012-01-27 激活fgf受体的3-o-烷基寡糖、其制备及其治疗用途
EP12703584.8A EP2668198A1 (fr) 2011-01-27 2012-01-27 3-o-alkyl-oligosaccharides activateurs de récepteur fgf, préparation de ceux-ci et utilisation thérapeutique de ceux-ci
JP2013550994A JP2014503674A (ja) 2011-01-27 2012-01-27 Ｆｇｆ受容体活性化３−ｏ−アルキルオリゴ糖類、これの調製およびこれの治療的使用
TW101102918A TW201236687A (en) 2011-01-27 2012-01-30 FGF receptor-activating 3-O-alkyl oligosaccharides, preparation thereof and therapeutic use thereof
US13/951,820 US20140094429A1 (en) 2011-01-27 2013-07-26 Fgf receptor-activating 3-o-alkyl oligosaccharides, preparation thereof and therapeutic use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150645A FR2970969B1 (fr) 2011-01-27 2011-01-27 Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2970969A1 FR2970969A1 (fr) 2012-08-03
FR2970969B1 true FR2970969B1 (fr) 2013-10-18

Family

ID=44484796

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1150645A Expired - Fee Related FR2970969B1 (fr) 2011-01-27 2011-01-27 Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique

Country Status (8)

Country Link
US (1) US20140094429A1 (fr)
EP (1) EP2668198A1 (fr)
JP (1) JP2014503674A (fr)
CN (1) CN103443114A (fr)
AR (1) AR084924A1 (fr)
FR (1) FR2970969B1 (fr)
TW (1) TW201236687A (fr)
WO (1) WO2012101605A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205115A2 (fr) 2013-06-19 2014-12-24 The Regents Of The University Of California Échange de silyle régiosélectif d'oligosaccharides per-silylés
CN108392485B (zh) * 2018-01-17 2021-05-11 浙江工业大学 硫酸化甘露葡萄糖醛酸寡糖在制备治疗或预防神经退行性疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300099A1 (fr) 1987-07-20 1989-01-25 Akzo N.V. Pentasaccharides
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
FR2704226B1 (fr) 1993-04-22 1995-07-21 Sanofi Elf 3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ES2147216T3 (es) 1993-09-01 2000-09-01 Akzo Nobel Nv Bisconjugados que comprenden dos sacaridos y un grupo de union.
FR2749849B1 (fr) * 1996-06-14 1998-09-04 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
JPH10310602A (ja) * 1997-05-09 1998-11-24 Ngk Insulators Ltd Ｎ−アセチルノイラミン酸ホモポリマーの硫酸エステルを用いた線維芽細胞増殖因子（ｆｇｆ）活性化組成物、ｎ−アセチルノイラミン酸ホモポリマーの硫酸エステルの合成方法、該合成方法で合成したｎ−アセチルノイラミン酸ホモポリマーの硫酸エステル
FR2773804B1 (fr) 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
SI1427427T1 (sl) * 2001-09-12 2011-10-28 Sigma Tau Res Switzerland Sa Derivati delno desulfatiziranih glikozaminglikanov kot heparanazni inhibitorji, z ohranjeno antiangiogeno aktivnostjo in brez antikoagulantnega uäśinka
FR2935387B1 (fr) * 2008-08-26 2010-09-10 Sanofi Aventis Hexadecasaccharides a activite antithrombotique comprenant une liaison covalente avec une chaine amine
WO2010029185A1 (fr) * 2008-09-15 2010-03-18 Endotis Pharma Composés d’oligosaccharide pour utilisation dans la mobilisation de cellules souches
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
FR2970969A1 (fr) 2012-08-03
EP2668198A1 (fr) 2013-12-04
AR084924A1 (es) 2013-07-10
WO2012101605A1 (fr) 2012-08-02
TW201236687A (en) 2012-09-16
US20140094429A1 (en) 2014-04-03
JP2014503674A (ja) 2014-02-13
CN103443114A (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
SA517390586B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MY162535A (en) Inhibitors of arginase and their therapeutic applications
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
JO3193B1 (ar) مشتقات ثينوبيريميدين جديدة وعملية لتحضيرها والتركيبات الدوائية التي تحتوي عليها
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MY182564A (en) 1, 2-substituted cyclopentanes as orexin receptor antagonists
GB201209587D0 (en) Therapeutic compounds
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
PH12015502632A1 (en) Cxcr7 receptor modulators
PH12014502285A1 (en) Anti-malarial agents
NI201600016A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los continen.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
FR2970969B1 (fr) Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
BR112017004868A2 (pt) derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20160930